Impact News +++ Progressive Reports June 2025 Results (GlobeNewswire EN) +++ PROGRESSIVE CORP Aktie +3,43%

ARBUTUS Aktie

>ARBUTUS Aktienkurs

2.716 EUR (Tradegate)

Ask: 2.762 EUR / 1090 Stück

Bid: 2.67 EUR / 1130 Stück

Tagesumsatz: 0 Stück

Realtime Kurs von 8 bis 22 Uhr!

ARBUTUS Aktie über LYNX handeln

Intraday

1 Jahr

>ARBUTUS Performance

1 Woche: -0,5%

1 Monat: -12,8%

3 Monate: -6,9%

6 Monate: -14,5%

1 Jahr: -21,0%

laufendes Jahr: -11,0%

>ARBUTUS Aktie

Name:

ARBUTUS BIOPHARMA

Land:

Kanada

Sektor:

Gesundheit

ISIN/ Wkn:

CA03879J1003 / A14XMD

Symbol/ Ticker:

I9DN (Frankfurt) / ABUS (NASDAQ)

Kürzel:

FRA:I9DN, ETR:I9DN, I9DN:GR, NASDAQ:ABUS

Index:

Webseite:

https://www.arbutusbio.co..

Marktkapitalisierung:

582.89 Mio. EUR

Umsatz:

5.54 Mio. EUR

EBITDA:

-57.3 Mio. EUR

Gewinn je Aktie:

-0.303 EUR

Schulden:

4.85 Mio. EUR

Liquide Mittel:

97.58 Mio. EUR

Umsatz-/ Gewinnwachstum:

15.1% / -

KGV/ KGV lG:

- / -

KUV/ KBV/ PEG:

102.64 / 8.4 / -

Gewinnm./ Eigenkapitalr.:

- / -79.02%

Dividende je Aktie:

Dividendenrendite/ -schätzung:

- / -

Insiderhandel:

Suchwörter:

ARBUTUS

Letzte Datenerhebung:

16.07.25

>ARBUTUS Eigentümer

Aktien: 191.53 Mio. St.

f.h. Aktien: 136.36 Mio. St.

Insider Eigner: 21.89%

Instit. Eigner: 59.44%

Leerverk. Aktien: 7.27%

>ARBUTUS Peer Group

AYR WELLNESS

CARDIOL

FENNEC

GREEN THUMB

HEALWELL AI

MIND MEDICINE

SIENNA SENIOR LIVING

THERALASE

TRULIEVE

WELL HEALTH

>ARBUTUS Chart & Kurs - NASDAQ

>ARBUTUS News

25.06.25 - 13:33	Arbutus Reacquires Greater China Rights to Imdusiran and Announces Scientific Advisory Board with Late-Stage Clinical Focus (GlobeNewswire EN)
	Qilu Pharmaceutical and Arbutus mutually agree to conclude strategic partnership for imdusiran in Greater China...

06.06.25 - 13:42	DataMetrex AI Ltd.: Datametrex Acquires Arbutus Health And Wellness Inc. (Accesswire)
	TORONTO, ON / ACCESS Newswire / June 6, 2025 / Datametrex AI Limited (the "Company" or "Datametrex') (TSXV:DM)(FSE:D4G)(OTC PINK:DTMXF) is pleased to announce that further to its news release dated......

14.05.25 - 16:00	Arbutus Biopharma (ABUS) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
	Arbutus (ABUS) delivered earnings and revenue surprises of -44.44% and 10.25%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?...

14.05.25 - 13:54	Arbutus Biopharma GAAP EPS of -$0.13 misses by $0.03, revenue of $1.76M beats by $0.17M (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

07.05.25 - 08:03	Arbutus Presents Clinical Trial Data from its Two HBV Assets, Imdusiran and AB-101, at the European Association for the Study of the Liver (EASL) Congress 2025 (GlobeNewswire EN)
	Data highlighted in late-breaker poster presentation shows that imdusiran achieves functional cure in chronic hepatitis B (cHBV) patients when combined with VTP-300 and low dose nivolumab...

24.04.25 - 17:30	Will Arbutus Biopharma (ABUS) Report Negative Q1 Earnings? What You Should Know (Zacks)
	Arbutus (ABUS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations....

23.04.25 - 08:03	Arbutus to Present Imdusiran and AB-101 Data at EASL Congress 2025 (GlobeNewswire EN)
	Five abstracts accepted for poster presentations...

01.04.25 - 14:15	DataMetrex signs LOI to acquire Arbutus Health and Wellness (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

01.04.25 - 13:42	DataMetrex AI Ltd.: DataMetrex Signs LOI to Acquire Arbutus Health and Wellness Inc. (Accesswire)
	TORONTO, ON / ACCESS Newswire / April 1, 2025 / Datametrex AI Limited (the "Company" or "Datametrex') (TSXV:DM)(FSE:D4G)(OTC PINK:DTMXF) is pleased to announce the signing of a non-binding Letter o......

31.03.25 - 19:45	All You Need to Know About Arbutus (ABUS) Rating Upgrade to Buy (Zacks)
	Arbutus (ABUS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy)....

27.03.25 - 15:01	Arbutus Biopharma (ABUS) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
	Arbutus (ABUS) delivered earnings and revenue surprises of 12.50% and 17.46%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?...

27.03.25 - 14:09	Arbutus announces a 57% workforce reduction (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

27.03.25 - 13:06	Arbutus Biopharma GAAP EPS of -$0.38 misses by $0.30, revenue of $6.17M beats by $4.65M (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

27.03.25 - 12:33	Arbutus Reports Fourth Quarter and Year End 2024 Financial Results and Provides Corporate Update (GlobeNewswire EN)
	Claim construction hearing for Pfizer/BioNTech mRNA-LNP vaccine litigation occurred in December 2024; outcome pending...

03.03.25 - 15:18

Genevant Sciences and Arbutus Biopharma Initiate International Patent Infringement Enforcement Actions Against Moderna (GlobeNewswire EN)

BASEL, Switzerland and VANCOUVER, British Columbia and WARMINSTER, Pa., March 03, 2025 (GLOBE NEWSWIRE) -- Genevant Sciences, a leading nucleic acid delivery company with world-class platforms and a robust lipid nanoparticle (LNP) patent portfolio (a subsidiary of Roivant Sciences, Ltd. (Nasdaq: ROIV)), and Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company focused on infectious disease, today filed five international lawsuits seeking to enforce patents protecting their innovative LNP technology against Moderna, Inc. and certain affiliates. Together, the enforcement actions target alleged infringing activities in 30 countries....

25.02.25 - 14:42	Arbutus appoints Lindsay Androski as CEO (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

06.02.25 - 02:01	Insiderhandel: Interim President & CEO verkauft Aktien von Arbutus Biopharma im Wert von 78103 USD (Insiderkauf)
	Mcelhaugh, Michael J. - Vorstand - Tag der Transaktion: 2025-02-04...

06.02.25 - 02:01	Insiderhandel: General Counsel and CCO verkauft Aktien von Arbutus Biopharma im Wert von 37206 USD (Insiderkauf)
	Naftzger, J. Christopher - Vorstand - Tag der Transaktion: 2025-02-04...

06.02.25 - 02:01	Insiderhandel: Chief Financial Officer verkauft Aktien von Arbutus Biopharma im Wert von 72827 USD (Insiderkauf)
	Hastings, David C. - Vorstand - Tag der Transaktion: 2025-02-04...

06.02.25 - 02:01	Insiderhandel: Chief Medical Officer verkauft Aktien von Arbutus Biopharma im Wert von 63519 USD (Insiderkauf)
	Sims, Karen - Vorstand - Tag der Transaktion: 2025-02-04...

>weitere News anzeigen...

>Impressum >Über uns >Datenschutz >Financial Data & Solutions

>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!

Zitat des Tages: Vollkommene Politik besteht darin, niemals das letzte Motiv zu enthüllen. - Benjamin Disraeli

Partner: >Tradegate Börse | >Dukascopy | >Boersentreff- Partner

Börsentreff auf Facebook |

Börsentreff auf X |

Börsentreff auf Instagram